RapaFusyn Pharmaceuticals — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

RapaFusyn Pharmaceuticals is a private, preclinical-stage biotech based in San Diego, founded in 2018. The company has developed a proprietary platform to create RapaGlues, a unique modality of non-degrading molecular glues that harness the FKBP12 chaperone to target intractable proteins. With a pipeline of eight disclosed programs across oncology and immunology & inflammation, the company is advancing its lead program towards IND and recently secured a significant $44 million Series A financing to fuel its platform and pipeline development.

OncologyImmunology & InflammationAcute Kidney Injury

Technology Platform

RapaGlues platform: proprietary non-degrading molecular glues that are cell-permeable macrocycles. They bind the intracellular chaperone FKBP12 and a target protein, inducing a neo-protein-protein interaction that inhibits the target's function without degradation. Inspired by natural FKBP12 binders like Rapamycin.

Opportunities

The platform offers a novel approach to drug the 'undruggable' proteome, particularly protein-protein interactions and intracellular domains, representing a massive untapped market in oncology and immunology.

Successful clinical validation of the lead program could trigger high-value partnerships or acquisition interest from large pharma.

The technology's applicability across multiple target classes allows for rapid pipeline expansion and out-licensing opportunities.

Risk Factors

The core technology is novel and unproven in humans, carrying significant translational risk from preclinical models to clinical efficacy and safety.

The company's value is highly concentrated in platform validation; failure of a lead program could severely impact valuation and funding.

It operates in a fiercely competitive landscape against other modalities (e.g., PROTACs, other molecular glues) from larger, better-resourced companies.

Competitive Landscape

RapaFusyn competes in the targeted protein modulation space, notably against developers of molecular glues that induce degradation (e.g., Monte Rosa Therapeutics, Neomorph) and bifunctional degraders like PROTACs (e.g., Arvinas, Kymera Therapeutics). Its key differentiation is the use of FKBP12 as a non-degrading glue, offering a potentially safer profile by avoiding off-target protein degradation. However, it must prove this advantage against established degradation-based approaches that have already reached the clinic.

More companies in United States →